[1] He is also the executive director[2] of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies[3] developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections.
The G7 Health Ministers have cited CARB-X[6] among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections.
[8] The same year, G20 Health Ministers cited CARB-X as playing a critical role in accelerating antimicrobial R&D and access.
The call recommended increasing public investment in push incentives to catalyze global antimicrobial R&D efforts and cited CARB-X as a push mechanism that should be mobilized due to CARB-X’s critical role in supporting the discovery and development or new antimicrobials.
[11] Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures.